Corlanor, Corlentor(ivabradine)
Corlanor, Corlentor, Ivabradine, Procoralan (ivabradine) is a small molecule pharmaceutical. Ivabradine was first approved as Procoralan on 2005-10-25. It is used to treat heart failure in the USA. It has been approved in Europe to treat angina pectoris and heart failure. It is known to target potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1, potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 2, potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, and potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 3.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
| signs and symptoms pathological conditions | D013568 |
Trade Name
FDA
EMA
Corlanor, Ivabradine
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| corlanor | New Drug Application | 2022-02-14 |
| ivabradine | ANDA | 2025-07-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| heart failure | EFO_0003144 | D006333 | I50 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
IVABRADINE, CORLANOR, AMGEN INC | |||
| 2026-10-22 | PED | ||
| 2026-04-22 | ODE-234 | ||
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01E: Other cardiac preparations in atc
— C01EB: Other plain cardiac preparations in atc
— C01EB17: Ivabradine
— C07: Beta-adrenergic blocking agents
— C07F: Beta blocking agents, other combinations
— C07FX: Beta blocking agents, other combinations
— C07FX05: Metoprolol and ivabradine
— C07FX06: Carvedilol and ivabradine
HCPCS
No data
Clinical
Clinical Trials
99 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | — | 4 | — | 4 |
| Tachycardia | D013610 | — | R00.0 | — | — | 1 | 1 | — | 2 |
| Left ventricular dysfunction | D018487 | — | — | — | — | — | 1 | — | 1 |
| Shock | D012769 | — | R57.1 | — | — | — | 1 | — | 1 |
| Cardiogenic shock | D012770 | — | R57.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postural orthostatic tachycardia syndrome | D054972 | — | G90.A | — | — | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | 1 | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
| Primary dysautonomias | D054969 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ivabradine |
| INN | ivabradine |
| Description | Ivabradine is a member of the class of benzazepines that is 7,8-dimethoxy-1,3,4,5-tetrahydro-3-benzazepin-2-one in which the amide hydrogen is replaced by a [{[(7S)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino]propyl} group. Used (as its hydrochloride salt) to treat patients with angina who have intolerance to beta blockers and/or heart failure. It has a role as a cardiotonic drug. It is a benzazepine, a tertiary amino compound, a carbobicyclic compound and an aromatic ether. It is a conjugate base of an ivabradine(1+). |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2 |
Identifiers
| PDB | — |
| CAS-ID | 155974-00-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL471737 |
| ChEBI ID | 85966 |
| PubChem CID | 132999 |
| DrugBank | DB09083 |
| UNII ID | 3H48L0LPZQ (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
HCN1
HCN1
HCN2
HCN2
HCN4
HCN4
HCN3
HCN3
Organism
Homo sapiens
Gene name
HCN1
Gene synonyms
BCNG1
NCBI Gene ID
Protein name
potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1
Protein synonyms
BCNG-1, Brain cyclic nucleotide-gated channel 1
Uniprot ID
Mouse ortholog
Hcn1 (15165)
potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (Q9D613)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,595 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,952 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use